Key insight: A letter in Nature Methods noting flaws in the CRISPR gene editing system spooked investors today, but it shouldn’t have — because we’ve long known about those problems.

A letter in Nature Methods pointing out potentially dangerous flaws in the CRISPR-Cas9 genome editing system gave biotech investors a sinking feeling on Tuesday, and stocks in genome-editing companies had the same experience. By the close of trading Editas Medicine had fallen nearly 12 percent, Crispr Therapeutics was down more than 5 percent, and Intellia Therapeutics had plunged just over 14 percent.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy